In modern gene therapy, antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) are key nucleic acid drugs that offer new treatment options for genetic and complex diseases.
Tenaya Therapeutics has administered the first dose to a patient in the Phase 1b clinical study of TN-401, part of the RIDGE™-1 trial, aimed at treating ARRVC linked to PKP2.
Novartis' Kisqali® has secured approval from the European Commission for use in a wide range of patients with HR+/HER2- early breast cancer who are at high risk of recurrence.